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Abstract 
In this study the in vitro activities of seven antibiotics (ciprofloxacin, ceftazidime, tetracycline, 
trimethoprim,  sulfamethoxazole,  polymyxin  B  and  piperacillin)  and  six  phytochemicals 
(protocatechuic acid, gallic acid, ellagic acid, rutin, berberine and myricetin) against five P. 
aeruginosa isolates, alone and in combination are evaluated. All the phytochemicals under 
investigation demonstrate potential inhibitory activity against P. aeruginosa. The combinations 
of sulfamethoxazole plus protocatechuic acid, sulfamethoxazole plus ellagic acid, sulfame-
thoxazole plus gallic acid and tetracycline plus gallic acid show synergistic mode of interaction. 
However, the combinations of sulfamethoxazole plus myricetin shows synergism for three 
strains (PA01, DB5218 and DR3062). The synergistic combinations are further evaluated for 
their  bactericidal  activity  against  P.  aeruginosa  ATCC  strain  using  time-kill  method. 
Sub-inhibitory dose responses of antibiotics and phytochemicals individually and in combina-
tion are presented along with their interaction network to suggest on the mechanism of ac-
tion and potential targets for the phytochemicals under investigation. The identified syner-
gistic combinations can be of potent therapeutic value against P. aeruginosa infections. These 
findings have potential implications in delaying the development of resistance as the anti-
bacterial effect is achieved with lower concentrations of both drugs (antibiotics and phyto-
chemicals). 
Key words: Synergy, combination therapy, phytochemicals, drug resistance. 
Introduction 
Pseudomonas  aeruginosa  is  a  major  nosocomial 
pathogen,  particularly  dangerous  to  cystic  fibrosis 
patients and populations having weak immune sys-
t e m .   M o r e o v e r ,   t h i s   o r g a n i s m   i s   r e s i s t a n t   t o   m a n y  
antibacterial drugs [1]. Several mechanisms for resis-
tance against antibiotics have been proposed - which 
include  antibiotic  inactivation  by  enzymatic  action, 
a l t e r i n g   t h e   e f f l u x   p u m p   m e c h a n i s m s ,   t a r g e t   m u t a-
tion, and decreased uptake of antibiotics [2].   D u e   t o  
the  frequent  development  of  resistance  during  mo-
notherapy  treatment  of  infected  patients,  multiple 
combinations  of  antibacterial  agents  are  proposed 
[3-4]. Synergy is reported for β-lactams in combina-
tion  with  aminoglycoside  antibiotics.  However,  the 
increasing resistance of Pseudomonas sp. to β-lactams 
and  the  toxicity  concerns  with  the  aminoglycosides 
limit the use of these combinations [5]. It is also re-
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with other antimicrobials to treat multidrug resistant 
(MDR)  gram-negative  respiratory  tract  infections 
caused by several clinical strains of P. aeruginosa [6]. 
Also,  fluoroquinolones  in  combination  with  potent 
anti-pseudomonal  β-lactam  agents  are  reported  to 
prevent the development of resistance in P. aeruginosa 
[7-8]. Earlier, Marie et al. reported that cystic fibrosis 
patients infected with P. aeruginosa can be effectively 
treated with clarithromycin/tobramycin combination 
[9].   H o w e v e r ,   a l a r m i n g l y   n u m b e r s   o f   P.  aeruginosa 
strains  are  reported  to  show  resistance  to  multiple 
antibiotics. Concomitantly, multidrug resistance and 
dual resistance are major issues in developing a de-
finitive therapy for P. aeruginosa infections [10]. 
S i n c e   l o n g ,   n a t u r a l   p r o d u c t s   a r e   i n   u s e   f o r   t h e  
de v e l o p m e n t   o f   n o v e l   d r u g s   t o   t r e a t   v a r i o u s   b a c t e r i a l  
infections. Several studies have proposed that natural 
compounds in combination with antibiotics are a new 
strategy for developing therapies for infections caused 
by bacterial species and that natural plant  products 
can potentiate the activity of antibiotics in combina-
tion [10-13]. For example, secondary metabolites like 
essential oils, flavonols and alkaloids have been re-
ported to have antimicrobial properties [14-18]. Also, 
M i c h a e l   a n d   c o l l e a g u e s   r e p o r t e d   t h a t   t h e   u s e   o f   b a c-
terial resistance modifiers such as efflux pump inhi-
bitors,  derived  from  natural  sources  mainly  from 
plants  can  suppress  the  emergence  of  MDR strains 
[19].  
Phenolic compounds from medicinal herbs and 
dietary plants possess a range of bioactivities like - 
antibacterial, antifungal, antiviral, antimutagenic and 
anti-inflammatory  activities.  Moreover,  extensive 
clinical evidence has shown that chemoprevention by 
phenolic  phytochemicals  is  an  inexpensive,  readily 
applicable  approach  in  the  chemotherapy  and  man-
agement  [20]. Here, we investigate the in vitro anti-
microbial activities of 7 different antibiotics (ciprof-
loxacin, ceftazidime, tetracycline, trimethoprim, sul-
famethoxazole,  polymyxin  B  and  piperacillin)  in 
combination  with  6  phytochemicals  (protocatechuic 
acid, gallic acid, ellagic acid, rutin, berberine and my-
ricetin) against 5 strains of  P.  aeruginosa  using mini-
mum  inhibitory  concentrations  (MIC),  checkerboard 
test, and time-kill assay. All antibiotics under inves-
tigation  have  earlier  been  reported  as  an-
ti-pseudomonal  drugs  and  have  been  reported  to 
have different mechanisms of action (have different 
t a r g e t s ) .   T h e   r e s u l t s   o f   o u r   a n a l y s i s   w i t h   d a t a   o n   a n t i-
biotic-phytochemical  interaction  network  are  pre-
sented. 
Materials and Methods 
Antimicrobial agents: 
Standard  powders  of  antibiotics  and  phyto-
chemicals listed in Table 1 were obtained from Sigma 
- Aldrich, Singapore. Stock solutions were prepared 
and  diluted  according  to  Clinical  and  Laboratory 
Standards  Institute  (CLSI)  standards  and  manufac-
turer's recommendations and stored at -20°C. 
Bacterial isolates: 
Five P. aeruginosa strains were u s e d   i n   t h i s   s t u d y  
including  two  clinical  isolates  (DB5218,  DR3062) 
which was obtained from Singapore General Hospit-
al, Singapore. The other three strains were P. aerugi-
nosa ATCC 15692 (American Type Culture Collection, 
Manassas,  USA),  P.  aeruginosa  PA01  (University  of 
Geneva, Switzerland), P. aeruginosa PT121 (University 
of  Geneva,  Switzerland).  Before  use,  bacterial  sus-
p e n s i o n   w a s   m a d e   f r o m   f r e s h   c u l t u r e   a n d   s t o r e d   a t  
-80⁰C using 30% glycerol.  
Antimicrobial susceptibility testing: 
MIC is defined as the lowest concentration of the 
antimicrobial agent that inhibits the bacterial growth 
a s   d e t e c t e d   b y   l a c k   o f   v i s u a l   t u r b i d i t y .  Broth micro-
d i l u t i o n   m e t h o d   w a s   u s e d   t o   d e t e r m i n e   t h e   M I C s   f o r   7  
antibiotics and 6 phytochemicals according to Clinical 
and  Laboratory  Standards  Institute  guidelines  [21]. 
T h e   m e d i u m   u s e d   f o r   t h e   b r o t h   m i c r o d i l u t i o n   t e s t   w a s  
Iso-sensitest Broth (ISB). For each strain of P. aerugi-
nosa,  three  to  five  colonies  were  transferred  from 
o v e r n i g h t   g r o w t h   p l a t e   i n t o   5   m l   o f   I S B   t o   a p p r o x-
imate the density of 0.5 McFarland standard and in-
cubated  at  35⁰C  for 2-3 h. This suspension with the 
inoculum  concentration  of  108 colony  forming  units 
( C F U / m l )   w a s   t h e n   d i l u t e d   t o   1 0 6 CFU/ml with the 
Iso-sensitest broth. Serial two-fold dilutions of all the 
antimicrobial  agents  with  the  following  concentra-
tions  (µg/ml):  ciprofloxacin  (0.06  -  32),  ceftazidime 
(0.25 - 32), trimethoprim (4 - 128), sulfamethoxazole (8 
- 512), tetracycline (4 - 128),  polymyxinpolymyxin B 
(0.25 - 32), piperacillin (0.25 - 32), protocatechuic acid 
(250 - 8000), ellagic acid (1000 - 16000), gallic acid (250- 
8000),  rutin  (1000  -  16000),  berberine  (1000-16000), 
myricetin  (100  -  1000)  were  prepared  with  ISB  and 
placed  in  96-well  microtiter  plates  and  the  lowest 
concentration inhibiting visible growth after 18-2 0   h   a t  
35⁰C was recorded as MIC. 
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Table 1: List of antibiotics and phytochemicals used in this study 
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Checkerboard assay: 
The activity of phytochemicals and antibiotics in 
combination was investigated using the checkerboard 
broth microdilution method. Two fold serial dilutions 
o f   t h e   a n t i b i o t i c   a n d   t w o   f o l d   s e r i a l   d i l u t i o n s   o f   t h e  
phytochemicals were prepared for every combination 
t e s t e d   a n d   5 0   µ l   a l i q u o t s   o f   e a c h   c o m p o n e n t   w a s  
p l a c e d   i n t o   t h e   w e l l s   o f   t h e   s t e r i l e   9 6 -well microtiter 
plate.  The  inoculum  was  prepared  using  the  above 
described MIC determination method. The microtiter 
plates were then incubated at 35⁰C   a n d   M I C   w a s   d e-
termined after 18-20 h of incubation.  
The Fractional inhibitory concentration (FIC in-
dex) for all the combinations was determined using 
the following formula, 
FIC index = FICA + FICB = [A]/MICA + [B]/MICB 
FICA, FICB – Fractional inhibitory concentration 
o f   d r u g   A   &   B   r e s p e c t i v e l y .   
MICA, MICB – Minimum inhibitory concentration of 
drug A & B respectively. 
[A], [B] – Concentration of drug A & B respec-
tively. Int. J. Biol. Sci. 2010, 6 
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F I C   i n d e x   b y   c h e c k e r b o a r d   m e t h o d   i s   i n t e r-
preted as follows: ≤ 0.5- s y n e r g y ;   >   0 . 5   a n d   ≤   4 - addi-
tivity; and > 4 - antagonism. 
The  effects  of  sub-inhibitory  concentrations  of 
test compounds individually and in combination on 
PA01 growth were also evaluated by measuring the 
g r o w t h   r a t e s   a f t e r   2 0   h   o f   i n c u b a t i o n   a t   3 5 ⁰C in mi-
crotitre plates and OD600 was measured. 
Time-kill assay: 
Time-kill assays were performed using the iden-
tified synergistic combinations (SMX plus PA, SMX 
p l u s   E A ,   S M X   p l u s   G A   a n d   T E T   p l u s   G A )   a g a i n s t   a  
single bacterial isolate (ATCC 15692). Individual co-
l o n i e s   w e r e   i s o l a t e d   f r o m   t h e   o v e r n i g h t   g r o w t h   p l a t e  
a n d   s u s p e n d e d   i n   s t e r i l e   I S B   t o   a p p r o x i m a t e   t h e   d e n-
s i t y   o f   0 . 5   M c F a r l a n d   s t a n d a r d .   T h e   s u s p e n s i o n   w a s  
diluted 1:10 in ISB to obtain a standard inoculum of 1 
x 106 C F U / m l .   1 0 0   µ l   o f   t h e   d i l u t e d   s u s p e n s ion  was 
a d d e d   t o   0 . 9   m l   o f   I S B .   D o u b l e   d i l u t i o n s   f o r   e a c h   a n-
tibiotic  and  phytochemicals  were  prepared.  Tubes 
containing  individual  drugs  and  the  combination 
w e r e   i n c u b a t e d   a t   3 5 ° C   f o r   2 4   h .   F r o m   e a c h   t u b e   1 0 0   µ l  
o f   s a m p l e   w a s   r e m o v e d   a t   0 ,   4 ,   8   a n d   2 4   h ,   r espec-
t i v e l y   a n d   p l a t e d   t o   c o u n t   t h e   v i a b l e   c e l l s .   G r o w t h  
control  and  sterility  control  were  included  for  each 
assay.  The  killing  rate  was  determined  by  plotting 
viable colony counts (CFU/ml) against time. Synergy 
was defined as a ≥2 log10 CFU/ml decrease of viable 
count  by  the  combination  compared  with  the  most 
active single agent. 
Statistical analysis: 
T h e   d o s e   r e s p o n s e   v a l u e s   a n d   t i m e -kill data are 
presented  as  mean  ±  SD  (Standard  deviation).  The 
analysis was performed in triplicate.  
Results 
Antimicrobial susceptibility testing: 
This study explored the antimicrobial activities 
of the phytochemicals alone and in combination with 
7  anti-pseudomonal  drugs  (antibiotics)  against  5 
strains  of  P. aeruginosa (including 2 clinical strains). 
A l l   t h e   5   s t r a i n s   o f   P. aeruginosa w e r e   s u s c e p t i b l e   t o   t h e  
anti-pseudomonal drugs chosen for investigation i.e. 
ciprofloxacin,  ceftazidime,  trimethoprim,  sulfame-
thoxazole, tetracycline, polymyxin B and piperacillin. 
M I C   v a l u e   w a s   f o u n d   t o   b e   h i g h e s t   f o r   s u l f a m e t h o x-
azole  (128µg/ml)  and  lowest  for  ciprofloxacin 
(0.125µg/ml) among the antibiotics (Table 2).  
The  phytochemicals  used  in  this  study  signifi-
cantly inhibited the growth of all the bacterial strains 
under  investigation.  Among  the  phytochemicals 
tested,  myricetin  (500µg/ml),  protocatechuic  acid 
(2000µg/ml)  and  gallic  acid  (2000µg/ml)  showed 
l o w e r   M I C   t h a n   e l l a g i c   a c i d   ( 4 0 0 0 µ g / m l ) ,   r u t i n  
(4000µg/ml)  and  berberine  (4000µg/ml).  The  mini-
mum inhibitory concentrations of the phytochemicals 
are listed in Table 2. 
 
Table 2: Antimicrobial activity (MIC values) of all the an-
tibiotics and phytochemicals against five strains of P. aeru-
ginosa 
Antimicrobials  Minimum inhibitory concentration (µg/ml) 
P. aeruginosa strains 
ATCC  PA01  PT121  DB5218 
 
DR3062 
Ciprofloxacin  0.125  0.125  0.125  0.125  0.25 
Ceftazidime  2  2  2  4  8 
Trimethoprim  32  32  32  32  32 
Sulfamethoxazole  128  128  128  128  128 
Tetracycline  32  32  32  32  32 
Polymyxin B  2  2  2  2  2 
Piperacillin  2  2  2  2  16 
Protocatechuic acid  2000  2000  2000  2000  2000 
Ellagic acid  4000  4000  4000  4000  4000 
Gallic acid  2000  2000  2000  2000  2000 
Rutin  4000  4000  4000  4000  4000 
Berberine  4000  4000  4000  4000  4000 
Myricetin  500  500  500  500  500 
 
 
Combination of phytochemicals and antibiotics against P. 
aeruginosa: 
The  combination  effects  of  anti-pseudomonal 
drugs and phytochemicals are summarized in Table 3.  
O u r   r e s u l t s   s h o w   t h a t   t h e   c o m b i n a t i o n s   o f   s u l-
famethoxazole  plus  protocatechuic  acid,  sulfame-
thoxazole plus ellagic acid and sulfamethoxazole plus 
gallic acid have synergistic mode of interactions for all 
the strains of P. aeruginosa under investigation. It was 
also  observed  that  the  antifolate  drug,  sulfamethox-
azole  is  synergistic  with  myricetin  in  three  strains 
(PA01,  DB5218  and  DR3062)  and  additive  for  two 
strains  (ATCC  and  PT121)  of  P. aeruginosa. Also, te-
tracycline  in  combination  with  gallic  acid  demon-
strates synergy for all the isolates under investigation. 
Other  antimicrobials  –  ciprofloxacin,  ceftazidime, 
trimethoprim,  polymyxin  B  and  piperacillin  show 
additivity in combination with phytochemicals, for all 
the strains under investigation. It is noteworthy, that 
none  of  the  antibiotic  -phytochemical  combinations 
show antagonism.  
The  FIC  indices  of  the  combinations  sulfame-
thoxazole plus protocatechuic acid and sulfamethox-
azole plus ellagic acid range from 0.25 – 0.5, showing 
significant synergistic activity for all the strains under 
investigation (Table 3). Int. J. Biol. Sci. 2010, 6 
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Table 3: I n   v i t r o  activity of all antimicrobial combinations against fiv e   s t r a i n s   o f   P. aeruginosa. T h e   v a l u e s   s h o w   t h e   F I C   i n d e x .  
Antibiotics + 
Phytochemicals 
Combination 
P. aeruginosa strains 
ATCC  PA01  PT121  DB5218  DR3062 
Checkerboard FIC index (Interpretation) 
           
CIP+PA  2(I)  2(I)  2(I)  2(I)  1(I) 
CIP+EA  2(I)  2(I)  2(I)  2(I)  1(I) 
CIP+GA  2(I)  2(I)  2(I)  2(I)  1(I) 
CIP+RUT  1(I)  1(I)  1(I)  1(I)  1(I) 
CIP+BER  2(I)  2(I)  2(I)  2(I)  1(I) 
CIP+MYR  2(I)  2(I)  2(I)  2(I)  2(I) 
           
CF+PA  1(I)  1(I)  1(I)  1(I)  1(I) 
CF+EA  1(I)  1(I)  1(I)  2(I)  1(I) 
CF+GA  1(I)  1(I)  1(I)  2(I)  1(I) 
CF+RUT  1(I)  1(I)  1(I)  1(I)  2(I) 
CF+BER  1(I)  1(I)  1(I)  1(I)  2(I) 
CF+MYR  1(I)  1(I)  1(I)  1(I)  2(I) 
           
TMP+PA  1(I)  1(I)  1(I)  1(I)  1(I) 
TMP +EA  1(I)  1(I)  1(I)  1(I)  1(I) 
TMP +GA  1(I)  1(I)  1(I)  1(I)  1(I) 
TMP +RUT  2(I)  2(I)  2(I)  2(I)  2(I) 
TMP +BER  2(I)  2(I)  2(I)  2(I)  2(I) 
TMP +MYR  2(I)  2(I)  2(I)  2(I)  2(I) 
           
SMX+PA  0.5(S)  0.25(S)  0.25(S)  0.25(S)  0.25(S) 
SMX +EA  0.5(S)  0.25(S)  0.25(S)  0.25(S)  0.25(S) 
SMX +GA  0.5(S)  0.5(S)  0.5(S)  0.5(S)  0.5(S) 
SMX +RUT  1(I)  1(I)  1(I)  1(I)  1(I) 
SMX +BER  1(I)  1(I)  1(I)  1(I)  1(I) 
SMX +MYR  1(I)  0.5(S)  1(I)  0.5(S)  0.5(S) 
           
TET+PA  1(I)  1(I)  1(I)  1(I)  1(I) 
TET +EA  1(I)  1(I)  1(I)  1(I)  1(I) 
TET +GA  0.5(S)  0.5(S)  0.5(S)  0.5(S)  0.5(S) 
TET +RUT  1(I)  1(I)  1(I)  1(I)  1(I) 
TET +BER  1(I)  1(I)  1(I)  1(I)  1(I) 
TET +MYR  1(I)  1(I)  1(I)  1(I)  1(I) 
           
POL B+PA  2(I)  2(I)  2(I)  2(I)  2(I) 
POL B +EA  2(I)  2(I)  2(I)  2(I)  2(I) 
POL B +GA  2(I)  2(I)  2(I)  2(I)  2(I) 
POL B +RUT  2(I)  2(I)  2(I)  2(I)  2(I) 
POL B +BER  2(I)  2(I)  2(I)  2(I)  2(I) 
POL B +MYR  4(I)  4(I)  4(I)  4(I)  4(I) 
           
PIP+PA  1(I)  1(I)  1(I)  1(I)  1(I) 
PIP+EA  2(I)  2(I)  2(I)  2(I)  1(I) 
PIP+GA  1(I)  1(I)  1(I)  1(I)  1(I) 
PIP+RUT  2(I)  2(I)  2(I)  2(I)  2(I) 
PIP+BER  1(I)  1(I)  1(I)  1(I)  2(I) 
PIP+MYR  2(I)  2(I)  2(I)  2(I)  4(I) 
S = Synergistic; I = Additivity/Indifferent. 
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T h e   g r o w t h   i n h i b i t o r y   p r o p e r t i e s   o f   a l l   t h e   t e s t  
compounds and additive combinations assayed over 
20 h period in microtiter wells at sub-inhibitory con-
c e n t r a t i o n   w a s   s i m i l a r   t o   t h e   g r o w t h   c o n t r o l   w e l l   ( n o  
antimicrobials).  Moreover,  the  synergistic  combina-
tions  were  found  to  inhibit  the  test  strain  (PA01) 
g r o w t h   a t   s i m i l a r   c o n c e n t r a t i o n s   ( F i g u r e   1 ) .   T h e   d r u g  
interaction data between various classes of antibiotics 
a n d   p h y t o c h e m i c a l s   i s   r e p r e s e n t e d   a s   a   f i g u r e   t o   p r o-
vide  some  insi g h t s   o n   t h e i r   m e c h a n i s m   o f   a c t i o n  
(Figure 2).  
 
 
 
 
 
Fig.  1:  PA01 growth in subminimum inhibitory concentrations of individual antibiotics and phytochemicals and their 
combination. Dose response and classification of interactions for antibiotics and phytochemicals used in this study. Each 
panel consists of bars representing measured growth rates (OD600 nm) after 24 hr incubation with sub-inhibitory concen-
tration of the antimicrobials, from left to right: growth control (no antibiotics), antibiotics alone (1/4 x MIC), phytochemicals 
alone (1/4 x MIC), antibiotics + phytochemicals (1/4 + 1/4 x MIC). The background colour represents the type of interac-
tions, red – additive/indifferent, green – synergistic. Int. J. Biol. Sci. 2010, 6 
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Fig. 2: Network interactions between antibiotics and phytochemicals. Antibiotics are classified based on their respective 
targets and mechanism of action. CE, ceftazidime; PI, piperacillin - cell wall inhibitors; T, trimethoprim; S, sulfamethoxazole 
– folic acid biosynthesis inhibitors; POL B, polymyxin B – cell membrane inhibitors; TET, tetracycline – 30S ribosome 
inhibitors; CIP, ciprofloxacin – DNA gyrase and toposiomerase IV inhibitors. Phytochemicals are classified based on their 
classes. PA, protocatechuic acid; GA, gallic acid; EA, ellagic acid –polyphenol antioxidants (phenolic acids); BER, berberine – 
alkaloid; RUT, rutin; MYR, myricetin – flavonoids. 
 
Time-kill curves: 
Time-kill assays for the most potent synergistic 
combinations  (sulfamethoxazole  plus  protocatechuic 
acid,  sulfamethoxazole  plus  ellagic  acid,  sulfame-
thoxazole plus gallic acid and tetracycline plus gallic 
a c i d )   o n   A T C C   s t r a i n   a r e   s h o w n   ( F i g u r e s   3 :   A -D). The 
n e t   r e d u c t i o n   i n   c o l o n y   c o u n t   w a s   s e e n   c o n s i s t e n t l y  
(throughout  24  h)  at  (1/2th  +  1/2th)   x   M I C   f o r   t h e  
identified  synergistic  drug-herb  combinations.  Any 
single active agent alone at 1/2th x   M I C   d i d   n o t   s h o w  
significant inhibition of the isolates tested. The rate of 
k i l l i n g   w a s   h i g h e r   a t   8   h   w i t h   m a x i m u m   r e d u c t i o n   i n  
the colony count at 24 h. When 1/2th x   M I C   s u l f a m e-
thoxazole  was  combined with  1/2th x MIC protoca-
techuic acid, 1/2th x   M I C   s u lfamethoxazole was com-
bined with 1/2th x MIC gallic acid, 1/2th x MIC tetra-
cycline was combined with 1/2th x MIC gallic acid, 
significant decrease in bacterial count was observed 
between  8  –  2 4   h   w i t h   m a x i m u m   r e d u c t i o n   i n   t h e  
g r o w t h   b a s e l i n e   b y   4   –  5  log10  CFU/ml.  However, 
when  1/2th  x MIC sulfamethoxazole was combined 
with 1/2th x MIC ellagic acid a reduction of 1 - 2 log10 
decrease in viable count occurred at 24 h.  
Discussion 
P. aeruginosa is a tenacious pathogen because of 
its ability to develop resistance to multiple antibiotics. 
Though, there are a few anti-pseudomonal drugs in 
the pipeline [22], there is an urgent need for novel and 
effective infection control strategy to face this highly 
c r i t i c a l   t h e r a p e u t i c   c h a l l e n g e   o f   d r u g   r e s i s t a n c e  
[23-24]. 
Since  long,  bioactive  compounds  from  natural 
sources have shown the potential to inhibit resistance 
mechanisms [25]. Here, we report on the synergistic 
and  additive  interactions  between  selected  phyto-
chemicals and antibiotics which are folate biosynthe-
sis inhibitors, DNA/protein synthesis inhibitors, and 
cell permeability/cell wall inhibitors.  Int. J. Biol. Sci. 2010, 6 
 
http://www.biolsci.org 
564 
Antibiotics and phytochemicals - interaction analysis  
Folate Biosynthesis inhibitors: 
Sulfamethoxazole (a sulfonamide), competitive-
ly  inhibits  the  binding  of  para  aminobenzoic  acid 
(pABA)  to  the  enzyme  dihydropteroate  synthase 
(DHPS) that catalyses the formation of dihydrofolate 
[26].  Trimethoprim  inhibits  dihydrofolate  reductase 
(DHFR)  enzyme  which  catalyses  the 
NADPH-dependent  reduction  of  dihydrofolate  to 
tetrahydrofolate,  an  important  cofactor  involved  in 
supplying  one  carbon  for  the  synthesis  of  purines, 
pyrimidines, methionine and  many  other amino  ac-
i d s .   I t   m u s t   b e   m e n t i o n e d   t h a t   n e a r l y   a l l   p r o karyotes 
must  synthesize  folate  compounds  de novo,  starting 
with GTP and utilizing several different enzymes in a 
multi-step  pathway,  whereas  eukaryotes  (including 
human) are able to utilize the dietary folates by up-
take through a carrier-mediated transport system [27]. 
Hence, DHF R   a n d   D H P S   a r e   g o o d   t a r g e t s   f o r   a n t i f o-
lates [28]. 
Recently,  we  proposed  that  phytochemicals 
(protocatechuic acid,   g a l l i c   a c i d ,   q u e r c e t i n   a n d   m y r i-
cetin)  possibly  bind  to  P.  aeruginosa  DHFR  and  in 
combination with sulfamethoxazole may inhibit dif-
ferent steps in the same pathway, thereby resulting in 
s y n e r g i s t i c   m o d e   o f   a c t i o n .   O n   t h e   o t h e r   h a n d   i n d i f-
ferent/additive  interaction  of  trimethoprim  and 
p h y t o c h e m i c a l s   m a y   b e   d u e   t o   t h e   b i n d i n g   o f   t h e s e  
phytochemicals  into  the  active  site  cavity  of  DHFR, 
thereby resulting in interactions with common target 
residues  similar  to  that  of  trimethoprim,  leading  to 
competitive  inhibition  and  no  inhibition  of  cell 
growth  [29]. Here, we reconfirm the above findings 
using 5 strains - including two clinical strains- of  P. 
aerugoinosa  a n d   a l s o   p r o v i d e   d a t a   o n   M I C s ,   a n d  
time-kill. We further report on synergism between the 
combination of ellagic acid and sulfamethoxazole and 
propose similar mode of action, as ellagic acid may 
also  potentially  bind  in  P.  aeruginosa  DHFR  active 
site.However, combinations of sulfamethoxazole plus 
rutin, sulfamethoxazole plus berberine, trimethoprim 
plus rutin and trimethoprim plus berberine resulted 
in indifferent/additive mode of interaction.  
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F i g u r e   3 : Time-kill data for synergistic combinations at ½ x MIC against P. aeruginosa ATCC strain 15692. (A) Combinations 
of sulfamethoxazole (SMX) and protocatechuic acid (PA); (B) Combinations of sulfamethoxazole (SMX) and gallic acid (GA); 
(C) Combinations of sulfamethoxazole (SMX) and ellagic acid (EA); (D) Combinations of tetracycline (TET) and gallic acid 
(GA). Filled diamond, control; Filled square, antibiotics; Filled triangle, phytochemicals; Filled circle, antibiotic and phyto-
chemical combination. 
 
 
Protein synthesis (30S ribosome) inhibitor: 
Synergistic interactions were observed for com-
bin a t i o n   o f   t e t r a c y c l i n e   a n d   g a l l i c   a c i d   f o r   a l l   t h e   P. 
aeruginosa strains  under  investigation.  Sudano  et  al., 
reported  that  epigallocatechin  gallate  enhances  the 
tetracycline activity for resistant staphylococcal iso-
lates by impairment of tetracycline efflux   p u m p   a c-
tivity and increased intracellular retention of the drug 
leading to synergistic drug combination [30].  Since, 
gallic acid is a structural component of epigallocate-
chin galate, there is a possibility that it may behave 
similarly in combination with tetracycline. Additive 
mode of interactions was observed for combinations 
of tetracycline and protocatechuic acid, ellagic acid, 
rutin, berberine and myricetin for all the P. aeruginosa 
strains under investigation.  
DNA replication inhibitor: 
The  combinations  of  ciprofloxacin/ 
p h y t o c h e m i c a l s   w e r e   f o u n d   t o   b e   a d d i t i v e .   C i p r o f-
l o x a c i n   h a s   b e e n   e a r l i e r   r e p o r t e d   t o   h a v e   t w o   t a r g e t s  
( D N A   g y r a s e   a n d   D N A   t o p o i s o m e r a s e   I V )   [31].  It  is 
suggested that quercetin, inhibits supercoiling activity 
of  E.  coli  bacterial  gyrase  by  binding  to  the  ATP 
binding site of gyrase B [32]. I t   i s   a l s o   r e p o r t e d   t h a t 
quercetin  and  myricetin  bind  to  DNA  and  induce 
enzymic DNA breakage [33]. Recently, epigallocate-
chin gallate is reported to inhibit E. coli bacterial DNA Int. J. Biol. Sci. 2010, 6 
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gyrase  [34].  Bernard  et  al.  found  that  rutin  induces 
topoisomerase  IV-mediated  DNA  cleavage  and 
growth inhibition in E. coli  [35].  The  mechanism  of 
a c t i o n   o f   b e r b e r i n e   w a s   f o u n d   t o   b e   s i m i l a r   t o   t h a t   o f  
rifampicin  and  norfloxacin  possibly  targeting  RNA 
polyme r a s e ,   D N A   g y r a s e   a n d   t o p o i s o m e r a s e   I V   e n-
zymes  [36]. The present study interaction data from 
(Figure 2) shows similar mechanism of action of the 
above phytochemicals as DNA synthesis inhibitors by 
having  indifferent  activity  in  combination  with  ci-
profloxacin. 
Cell wall / cell membrane permeability inhibitors: 
Ceftazidime, causes cell lysis in P. aeruginosa due 
to its primary activity against membrane proteins to 
which penicillin is reported to bind [37]. Also,  quer-
c e t i n   i s   r e p o r t e d   t o   c a u s e   i n c r e a s e   i n   p e r m e a b i l i t y   o f  
the inner bacterial membrane and loss of membrane 
potential  [38]. On the other hand, galangin, a struc-
tural  analogue  of  quercetin,  induces  cytoplasmic 
membrane  interference  damage  and  potassium  lea-
kage leading to cell wall damage [39]. The correlation 
between  indifferent  activities  of  phytochemicals  in 
combination with ceftazidime from the experimental 
data may possibly suggest that these compounds may 
act  at  same  target  either  at  different  sites  in  the  cy-
toplasmic membrane with direct contact with agonist 
site or at the same site. 
Polymyxin B is reported to have a detergent like 
mechanism  of  action  and  interacts  with  lipoplysac-
charide (LPS) of the outer membrane of P. aeruginosa 
[40-41]. Polymyxin B in combination with the tested 
phytochemicals results in additive/indifferent mode 
of interaction. The LPS molecules in the outer leaflet 
f o r m   s p e c i f i c   c o n t a c t s   w i t h   i n t e g r a l   o u t e r   m e m b r a n e  
proteins  and  ar e   r e q u i r e d   f o r   L P S   t r a n s p o r t   t o   t h e  
bacterial cell surface [42]. It is earlier suggested that in 
the  presence  of  lipopolysaccharid e   a s   a   b a r r i e r   i n  
gram-negative bacteria, the susceptibility of catechins 
may  be  low  [43]. The combinations of polymyxin B 
plus phytochemicals may help overcome this barrier 
d u e   t o   t h e   d e t e r g e n t   l i k e   a c t i v i t y   o f   p o l y m y x i n   B   a n d  
cytoplasmic  membrane  damage  inducing  ability  of 
phytochemicals.  However,  it  is  possible  that  there 
m a y   b e   a   d i r e c t   c o m p e t i t i o n   f o r   b i n d i n g   t o   L P S   o r   b y  
i n d i r e c t l y   a f f e c t i n g   t h e   s a m e   s i t e   o f   t h e   s a m e   t a r g e t   b y  
overlapping  actions  subsequently  resulting  in  addi-
tive mode of action. Similarly, piperacillin, an extened 
spectrum β-lactam antibiotic shows additive effect in 
combination with the phytochemicals under investi-
gation. 
This study highlights the various systemic inte-
raction  patterns  and  may  help  identify  new  drug 
combinations with novel mechanism of action. It must 
be  noted  that  no  antagonistic  interaction  was  ob-
s e r v e d   f o r   a n y   a n t i b i o t i c - phytochemical combination 
studied.  These  results  suggest  that  the  identified 
combinations could be potential and effective strate-
gy, without the concern of antagonistic interactions. 
O n e   o f   t h e   m a j o r   c oncerns  for  the  dietary  phyto-
chemicals under investigation is the higher MIC val-
ues in comparison to antibiotics, which are generally 
in the range of < 10 µg/ml  range  [44]. However, it is 
noteworthy that, the main polyphenol dietary sources 
are fruits and beverages with an average total intake 
o f   1 g / d a y   a n d   a f t e r   t h e   c o n s u m p t i o n   o f   1 0 -100 mg of 
a   s i n g l e   p h e n o l i c   c o m p o u n d ,   t h e   m a x i m u m   c o n c e n-
tration in plasma rarely exceeds 1 µM [45]. Addition-
ally the toxicity of these phytochemicals are very low 
and as of date, very few adverse side effects are re-
ported [46]. Nonetheless, detailed analysis needs to be 
carried out to characterize the interactions of antibac-
terial phytochemicals and antibiotics with the use of 
different approaches and methods facilitated by tar-
gets profile and toxicity data.  
Conclusion 
T h e   p r e s e n t   s t u d y   c l e a r l y   h i g h l i g h t s   t h e   l o w  
toxic  potential  of  phytochemicals  as  antibacterial 
compou n d s   a n d   s u g g e s t   o n   t h e   p o s s i b i l i t y   o f   u s e   o f  
t h e   a b o v e   s h o w n   s y n e r g i s t i c   d r u g -herb combinations 
for combating infections caused by this pathogen. The 
drug-h e r b   n e t w o r k   p r e s e n t e d   i n   t h i s   s t u d y   s h o w s   t h e  
level of interactions between various classes of anti-
biotics and phytochemicals and provides a baseline to 
identify  the  potential  mechanism  of  action  of  these 
potential phytochemicals. Moreover, phytochemicals 
a r e   r e p o r t e d   t o   h a v e   t h e   c a p a b i l i t y   o f   i n c r e a s i n g   t h e  
s u s c e p t i b i l i t y   o f   t h e   p a t h o g e n   t o   v a r i o u s   d r u gs  and 
a l s o   r e d u c e   t h e   t o x i c i t y   o f   t h e   d r u g s   w h e n   u s e d   i n  
combination.  Finally,  the  experimental  findings  en-
courage further studies with these agents and other 
antimicrobial classes and in vivo animal experiments 
to validate these interesting observations before clin-
ical  test  can  move  forward.  The  investigations  are 
u n d e r w a y   t o   f u r t h e r   c h a r a c t e r i z e   t h e   i n t e r a c t i o n   o f   t h e  
above phytochemicals and antibiotics. 
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34.  Gradiša r   H ,   P ristovšek P, Plaper A, et al. Green tea catechins 
inhibit  bacterial  DNA  gyrase  by  interaction  with  its  ATP 
binding site. Journal of Medicinal Chemistry. 2007; 50: 264-271. 
35.  Bernard FX, Sablé S, Cameron B, et al. Glycosylated flavones as 
selective inhibitors of topoisomerase IV. Antimicrobial Agents 
and Chemotherapy. 1997; 41: 992-998. 
36.  Yi ZB, Yan Y, Liang YZ, et al. Evaluation of the antimicrobial 
mode  of  berberine  by  LC/ESI-MS  combined  with  principal 
component analysis. Journal of Pharmaceutical and Biomedical 
Analysis. 2007; 44: 301-304. 
37.  H a y e s   M V ,   O r r   D C .   M o d e   o f   a c t i o n   o f   c e f t a z i d i m e :   A f f i n i t y   f o r  
the  penicillin-binding  proteins  of  Escherichia  coli  K12, 
Pseudomonas aeruginosa and Staphylococcus aureus. Journal 
of Antimicrobial Chemotherapy. 1983; 12: 119-126. Int. J. Biol. Sci. 2010, 6 
 
http://www.biolsci.org 
568 
38.  Mirzoeva OK, Grishanin RN, Calder PC. Antimicrobial action 
o f   p r o p o l i s   a n d   s o m e   o f   i t s   c o m p o n e n t s :   T h e   e f f e c t s   o n   g r o w t h ,  
membrane potential and motility of bacteria. Microbiological 
Research. 1997; 152: 239-246. 
39.  Cushnie  TPT,  Lamb  AJ.  Detection  of  galangin-induced 
cytoplasmic membrane damage in Staphylococcus aureus by 
measuring  potassium  loss.  Journal  of  Ethnopharmacology. 
2005; 101: 243-248. 
40.  Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: 
Old  antibiotics  for  emerging  multiresistant  gram-negative 
bacteria. Annals of Pharmacotherapy. 1999; 33: 960-967. 
41.  Hancock REW. Peptide antibiotics. Lancet. 1997; 349: 418-422. 
42.  B o s   M P ,   T o m m a s s e n   J .   B i o g e n e s i s   o f   t h e   G r a m -negative 
bacterial outer membrane. Current Opinion in Microbiology. 
2004; 7: 610-616. 
43.  Ikigai H, Nakae T, Hara Y, et al. Bactericidal catechins damage 
the  lipid  bilayer.  Biochimica  et  Biophysica  Acta  - 
Biomembranes. 1993; 1147: 132-136. 
44.  Clinical  and  Laboratory  Standards  Institute.  Performance 
Standards for Antimicrobial Susceptibility Testing: Twelfth In-
formational Supplement M100-S12.  Wayne,  PA:  Clinical  and 
Laboratory Standards Institute. 2002. 
45.  Scalbert A, Williamson G. Dietary intake and bioavailability of 
polyphenols. Journal of Nutrition. 2000; 130: 2073S-2085S. 
46.  B o d e   A M ,   D o n g   Z .   M o l e c u l a r   a n d   c e l l u l a r   t a r g e t s .   M o l  
Carcinog. 2006; 45: 422-430. 
47.  C h o p r a   I ,   R o b e r t s   M .   T e t r a c y c l i n e   a n t i b i o t i c s :   M o d e   o f   a c t i o n ,  
applications, molecular biology, and epidemiology of bacterial 
resistance. Microbiology and Molecular Biology Reviews. 2001; 
65: 232-260. 
48.  Iida K, Hirata S, Nakamuta S, et al. Inhibition of cell division of 
Escherichia  coli  by  a  new  synthetic  penicillin,  piperacillin. 
Antimicrobial Agents and Chemotherapy. 1978; 14: 257-266. 
49.  Ma s o n   T L ,   B r u c e   P   W .   I n a c t i v a t i o n   o f   r e d   b e e t   β -glucan 
synthase  by  native  and  oxidized  phenolic  compounds. 
Phytochemistry. 1987; 26: 2197-2202. 
50.  Mori A, Nishino C, Enoki N, et al. Antibacterial activity and 
mode of action of plant flavonoids against Proteus vulgaris and 
Staphylococcus aureus. Phytochemistry. 1987; 26: 2231-2234. 